Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894101188> ?p ?o ?g. }
- W2894101188 endingPage "106" @default.
- W2894101188 startingPage "84" @default.
- W2894101188 abstract "Improved understanding of the immune system and its role in cancer development and progression has led to impressive advances in the field of cancer immunotherapy over the last decade. Whilst the field is rapidly evolving and the list of drugs receiving regulatory approval for the treatment of various cancers is fast growing, the group of PD1- PDL-1 inhibitors is establishing a leading role amongst immunomodulatory agents. PD1- PDL-1 inhibitors act against pathways involved in adaptive immune suppression resulting in immune checkpoint blockade. Within the last four years two PD-1 and three PD-L1 inhibitors have been utilized in clinical practice against a variety of malignancies. Focus was initially placed on targeting cancers considered immunogenic such as melanoma, renal and lung cancers but subsequently the application expanded to include amongst others Hodgkin Lymphoma, urothelial as well as head and neck cancer. This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1- PDL-1 inhibitors in the corresponding cancer types. It presents available data on the combinations of PD1- PDL-1 inhibitors with other therapies (immunotherapy, targeted therapy and chemotherapy), the toxicity profile of the PD1- PDL-1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already. Finally, current and future challenges in the application of PD-1 and PD-L1 inhibitors are discussed with emphasis on the role of predictive biomarkers." @default.
- W2894101188 created "2018-10-05" @default.
- W2894101188 creator A5027462876 @default.
- W2894101188 creator A5030509820 @default.
- W2894101188 creator A5059314345 @default.
- W2894101188 date "2019-02-01" @default.
- W2894101188 modified "2023-10-16" @default.
- W2894101188 title "Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy" @default.
- W2894101188 cites W1538902372 @default.
- W2894101188 cites W1568317937 @default.
- W2894101188 cites W1580205301 @default.
- W2894101188 cites W1766682057 @default.
- W2894101188 cites W1785873212 @default.
- W2894101188 cites W1809627231 @default.
- W2894101188 cites W1939417476 @default.
- W2894101188 cites W1940241680 @default.
- W2894101188 cites W1942897646 @default.
- W2894101188 cites W1980980429 @default.
- W2894101188 cites W1982488143 @default.
- W2894101188 cites W1990189227 @default.
- W2894101188 cites W1990675339 @default.
- W2894101188 cites W2010121426 @default.
- W2894101188 cites W2016789384 @default.
- W2894101188 cites W2016983859 @default.
- W2894101188 cites W2039123767 @default.
- W2894101188 cites W2049553585 @default.
- W2894101188 cites W2056535502 @default.
- W2894101188 cites W2081795531 @default.
- W2894101188 cites W2083025888 @default.
- W2894101188 cites W2094548766 @default.
- W2894101188 cites W2096027620 @default.
- W2894101188 cites W2097200850 @default.
- W2894101188 cites W2097855813 @default.
- W2894101188 cites W2097995306 @default.
- W2894101188 cites W2098853737 @default.
- W2894101188 cites W2099044540 @default.
- W2894101188 cites W2100413206 @default.
- W2894101188 cites W2101653483 @default.
- W2894101188 cites W2103532863 @default.
- W2894101188 cites W2104347254 @default.
- W2894101188 cites W2104885590 @default.
- W2894101188 cites W2107752337 @default.
- W2894101188 cites W2112121482 @default.
- W2894101188 cites W2112434826 @default.
- W2894101188 cites W2114903025 @default.
- W2894101188 cites W2116302436 @default.
- W2894101188 cites W2118471749 @default.
- W2894101188 cites W2124060252 @default.
- W2894101188 cites W2125616358 @default.
- W2894101188 cites W2128035403 @default.
- W2894101188 cites W2128758225 @default.
- W2894101188 cites W2130506153 @default.
- W2894101188 cites W2135175382 @default.
- W2894101188 cites W2142300779 @default.
- W2894101188 cites W2143163879 @default.
- W2894101188 cites W2144608950 @default.
- W2894101188 cites W2147622445 @default.
- W2894101188 cites W2152897456 @default.
- W2894101188 cites W2156353875 @default.
- W2894101188 cites W2166662937 @default.
- W2894101188 cites W2171026458 @default.
- W2894101188 cites W2177804157 @default.
- W2894101188 cites W2198093519 @default.
- W2894101188 cites W2222086386 @default.
- W2894101188 cites W2233818050 @default.
- W2894101188 cites W2260067559 @default.
- W2894101188 cites W2289712604 @default.
- W2894101188 cites W2289851792 @default.
- W2894101188 cites W2293531514 @default.
- W2894101188 cites W2296947286 @default.
- W2894101188 cites W2300386653 @default.
- W2894101188 cites W2302126436 @default.
- W2894101188 cites W2337507927 @default.
- W2894101188 cites W2339890238 @default.
- W2894101188 cites W2345415641 @default.
- W2894101188 cites W2347070489 @default.
- W2894101188 cites W2397771749 @default.
- W2894101188 cites W2400514548 @default.
- W2894101188 cites W2401455386 @default.
- W2894101188 cites W2404869932 @default.
- W2894101188 cites W2412725897 @default.
- W2894101188 cites W2414977199 @default.
- W2894101188 cites W2418354692 @default.
- W2894101188 cites W2473218705 @default.
- W2894101188 cites W2473498748 @default.
- W2894101188 cites W2478834314 @default.
- W2894101188 cites W2479232428 @default.
- W2894101188 cites W2481467115 @default.
- W2894101188 cites W2504623699 @default.
- W2894101188 cites W2509217584 @default.
- W2894101188 cites W2510686645 @default.
- W2894101188 cites W2512310095 @default.
- W2894101188 cites W2515059140 @default.
- W2894101188 cites W2517381625 @default.
- W2894101188 cites W2519279652 @default.
- W2894101188 cites W2525717489 @default.
- W2894101188 cites W2526607882 @default.
- W2894101188 cites W2527905628 @default.